Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age28-36
SponsorTanta University
About this trial
This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.
Eligibility criteria
Qualifiers
Prematurity.
Gestational age between 28 and 36 weeks.
Suffering from respiratory distress syndrome.
Disqualifiers
Intrauterine growth restriction (IUGR).
Hypoxic ischemic encephalopathy.
Multiple congenital anomalies.
Chromosomal abnormalities.
Trial design
Treatments tested in this trial
- Serum endocan
- Serum copeptin
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov